Skip to main content
IMDX
NASDAQ Life Sciences

第二项研究证实iMDx GraftAssure 优越性，实现首个移植排斥“规则性纳入”选项

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$4.89
Mkt Cap
$157.199M
52W Low
$2.33
52W High
$8.51
Market data snapshot near publication time

summarizeSummary

Insight Molecular Diagnostics宣布在Transplant International上发表第二项同行评议研究，证实其GraftAssure检测的专有dd-cfDNA组合模型（CM）-评分的优越性。该研究表明CM评分与临床上重要的移植排斥指数之间存在强烈的相关性，优于其他衡量标准。这是在2025年世界移植大会上呈现的之前的正面数据之后，并建立在公司最近关于GraftAssure产品的关键里程碑公告之上，强化了其临床区别。该研究强调了该检测的能力，可以提供“前所未有的”80%以上的阳性预测值，实现“首次移植器官排斥的规则性纳入选项”。这是一个重要的临床进展，可能会在20亿美元以上的可寻址移植排斥检测市场中占据大量份额，从而对公司的收入潜力产生重大影响。投资者将继续关注进一步的商业化更新和监管进展，因为iMDx旨在于2026年将该诊断测试套件交付用于临床使用。

在该公告发布时，IMDX的交易价格为$4.89，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.6亿。 52周交易区间为$2.33至$8.51。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed IMDX - Latest Insights

IMDX
Apr 27, 2026, 7:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Broadwood Partners Increases Stake to 39.7%, Signals Intent for Shareholder Value Creation
Sentiment: Positive
View Wiseek Article
IMDX
Apr 27, 2026, 7:08 PM EDT
Filing Type: 4
Importance Score:
9
Broadwood Partners, a 10% owner, significantly increases stake in Insight Molecular Diagnostics with over $2M in new purchases
Sentiment: Positive
View Wiseek Article
IMDX
Apr 20, 2026, 7:24 PM EDT
Filing Type: 4
Importance Score:
8
10% Owner Broadwood Partners Increases Stake with $652K Open Market Purchase
Sentiment: Positive
View Wiseek Article
IMDX
Apr 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
iMDx's GraftAssure Assay Gains Momentum with New Clinical Data, FDA Submission Details
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:13 PM EDT
Filing Type: 10-K
Importance Score:
8
Insight Molecular Diagnostics Resolves Going Concern, Secures $24.6M in New Capital, and Submits Key Product to FDA
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Insight Molecular Diagnostics Submits Key Transplant Diagnostic for FDA Review, Reports Q4 Results
Sentiment: Positive
View Wiseek Article
IMDX
Mar 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Second Study Affirms iMDx GraftAssure Superiority, Enabling First-Ever Transplant Rejection 'Rule-In' Option
Sentiment: Positive
View Wiseek Article
IMDX
Mar 03, 2026, 8:07 AM EST
Source: Reuters
Importance Score:
8
Graftassuredx Advances Toward FDA Submission as Insight Molecular Diagnostics Completes Key Milestones
Sentiment: Positive
View Wiseek Article
IMDX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Insight Molecular Diagnostics Partners with Quest Diagnostics for GraftAssureCore™ Test Collection
Sentiment: Positive
View Wiseek Article
IMDX
Feb 12, 2026, 7:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Activist Investor Broadwood Partners Increases Stake to 37.4% with $3M Premium Purchase
Sentiment: Positive
View Wiseek Article